Pipex Pharmaceuticals To Acquire Exclusive Worldwid License To Use Oral Flupirtine for Diabetes, Diabetic Retinopathy, Retinities Pigmentosa & Glaucoma Treatment
The Pharmaceutical company Pipex Pharmaceutical has announced its plan to acquire worldwide license to the issued and pending patent applications related to additional uses of oral flupirtine for the treatment of a range of ophthalmic, diabetes and diabetes-related therapeutic indications.
Steve H. Kanzer, CEO and the Chairman of the company said that they are pleased to enter into this agreement to license this intellectual property to enhance our patent estate for flupirtine and complement our ophthalmic franchise which includes oral zinc-monocysteine and it has already completed an 80-patient, six month, double-masked, placebo-controlled phase II clinical trial for dry age-related macular degeneration (AMD).
The potential therapeutic indications covered by the additional intellectual property estate include glaucoma, age-related macular degeneration (AMD), retinitis pigmentosa (RP), diabetic maculopathy, and diabetic retinopathy and are supported by existing human clinical data generated in European countries where flupirtine has been commercially available for over 20 years and used by an estimated 1.5 million patients. The intellectual property is supported by promising multi-year clinical experience of oral flupirtine in over 100 patients with diabetic retinopathy, maculopathy, retinitis pigmentosa and glaucoma.
Source: CNN
Filed under Diabetes, Diabetes Drug, Eye
